These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer. Shastry M; Jacob S; Rugo HS; Hamilton E Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269 [TBL] [Abstract][Full Text] [Related]
9. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan. Schreiber AR; O'Bryant CL; Kabos P; Diamond JR Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278 [TBL] [Abstract][Full Text] [Related]
10. Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis. Gadaleta-Caldarola G; Lanotte L; Infusino S; Gadaleta-Caldarola A; Schipilliti FM; Citrigno C; Petrarota C; Cusmai A; Rizzo A Cancer Treat Res Commun; 2023; 37():100775. PubMed ID: 37956525 [TBL] [Abstract][Full Text] [Related]
11. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Okajima D; Yasuda S; Maejima T; Karibe T; Sakurai K; Aida T; Toki T; Yamaguchi J; Kitamura M; Kamei R; Fujitani T; Honda T; Shibutani T; Muramatsu S; Nakada T; Goto R; Takahashi S; Yamaguchi M; Hamada H; Noguchi Y; Murakami M; Abe Y; Agatsuma T Mol Cancer Ther; 2021 Dec; 20(12):2329-2340. PubMed ID: 34413126 [TBL] [Abstract][Full Text] [Related]
12. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. Rugo HS; Bianchini G; Cortes J; Henning JW; Untch M ESMO Open; 2022 Aug; 7(4):100553. PubMed ID: 35964548 [TBL] [Abstract][Full Text] [Related]
13. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape. Adams E; Wildiers H; Neven P; Punie K ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076 [TBL] [Abstract][Full Text] [Related]
14. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC). Parisi C; Mahjoubi L; Gazzah A; Barlesi F Cancer Treat Rev; 2023 Jul; 118():102572. PubMed ID: 37230055 [TBL] [Abstract][Full Text] [Related]
15. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles. Fenton MA; Tarantino P; Graff SL Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377 [TBL] [Abstract][Full Text] [Related]
16. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843 [TBL] [Abstract][Full Text] [Related]
17. Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan. Bardia A; Harnden K; Mauro L; Pennisi A; Armitage M; Soliman H Oncologist; 2022 Aug; 27(8):637-645. PubMed ID: 35642907 [TBL] [Abstract][Full Text] [Related]